Unknown

Dataset Information

0

A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.


ABSTRACT: Background:Clinical trials of therapies directed against nodes of the signaling axis of phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin (mTOR) in glioblastoma (GBM) have had disappointing results. Resistance to mTOR inhibitors limits their efficacy. Methods:To determine mechanisms of resistance to chronic mTOR inhibition, we performed tandem screens on patient-derived GBM cultures. Results:An unbiased phosphoproteomic screen quantified phosphorylation changes associated with chronic exposure to the mTOR inhibitor rapamycin, and our analysis implicated a role for glycogen synthase kinase (GSK)3B attenuation in mediating resistance that was confirmed by functional studies. A targeted short hairpin RNA screen and further functional studies both in vitro and in vivo demonstrated that microtubule-associated protein (MAP)1B, previously associated predominantly with neurons, is a downstream effector of GSK3B-mediated resistance. Furthermore, we provide evidence that chronic rapamycin induces microtubule stability in a MAP1B-dependent manner in GBM cells. Additional experiments explicate a signaling pathway wherein combinatorial extracellular signal-regulated kinase (ERK)/mTOR targeting abrogates inhibitory phosphorylation of GSK3B, leads to phosphorylation of MAP1B, and confers sensitization. Conclusions:These data portray a compensatory molecular signaling network that imparts resistance to chronic mTOR inhibition in primary, human GBM cell cultures and points toward new therapeutic strategies.

SUBMITTER: Laks DR 

PROVIDER: S-EPMC5961175 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Clinical trials of therapies directed against nodes of the signaling axis of phosphatidylinositol-3 kinase/Akt/mammalian target of rapamycin (mTOR) in glioblastoma (GBM) have had disappointing results. Resistance to mTOR inhibitors limits their efficacy.<h4>Methods</h4>To determine mechanisms of resistance to chronic mTOR inhibition, we performed tandem screens on patient-derived GBM cultures.<h4>Results</h4>An unbiased phosphoproteomic screen quantified phosphorylation change  ...[more]

Similar Datasets

| S-EPMC6776692 | biostudies-literature
| S-EPMC9763154 | biostudies-literature
| S-EPMC5761544 | biostudies-literature
| S-EPMC4936927 | biostudies-literature
| S-EPMC4820873 | biostudies-literature
| S-EPMC6849413 | biostudies-literature
| S-EPMC3774279 | biostudies-literature
| S-EPMC9935518 | biostudies-literature
| S-EPMC5570309 | biostudies-literature
| S-EPMC3890826 | biostudies-literature